Explain the Controversy About the New Sublingual Sufentanil (Dsuvia)

March 2019

You'll hear about a new sublingual sufentanil tablet (Dsuvia, deh-SOO-vee-uh) for acute pain management.

It was initially developed for battlefield use.

But FDA approval of this potent opioid during the opioid epidemic...with its easy-to-administer dosage form...is stirring up concerns.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote